What is IgG4? A review of the biology of a unique immunoglobulin subtype

Current Opinion in Rheumatology

Volumn 23, Issue 1, 2011, Pages 119-124

  Nirula, Ajay ^a   Glaser, Scott M ^a   Kalled, Susan L ^a   Taylora, Frederick R ^a  

^a BIOGEN   (United States)

Author keywords

effector function; half antibody exchange; IgG4; IgG4 related systemic disease; interleukin 21

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; CLENOLIXIMAB; ECULIZUMAB; GEMTUZUMAB OZOGAMICIN; IBALIZUMAB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 21; LEBRIKIZUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASTHMA; CROHN DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGLOBULIN G4 RELATED SYSTEMIC DISEASE; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; TH2 CELL; TREATMENT RESPONSE;

ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN G; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; TH2 CELLS;

EID: 78650479011     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283412fd4     Document Type: Article

References (41)

1. Abbas A, Lichtman AH, PoberJS. Cellular and molecular immunology. 4th ed. New York, USA: WB Saunders; 2000.
2. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2006; 125:S73-S80.
3. Meulenbroek AJ, Zeijlemaker WP. Human IgG Subclasses: useful diagnostic markers for immunocompetence [online]. Sanquin, Laboratory for Experimental and Clinical Immunology University of Amsterdam, the Netherlands; 1996 (http://www.xs4all.nl/~ednieuw/IgGsubclasses/subkl.htm).
4. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25:1369-1372.
5. Morrell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673-680.
6. Aucouturier A, Danon F, Daveau M, et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immunol Methods 1984; 74:151-162.
7. French MA. Serum IgG subclasses in normal adults. Monogr Allergy 1986; 19:100-107.
8. Lefranc M-P, Giudicelli V, Ginestoux C, et al. IMGT®, the international ImMunoGeneTics information system® Nucleic Acids Res 2009; 37(Suppl 1):D1006-D1012.
9. Feldmann M, Charles P, Taylor P, et al. Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 1998; 20:211-228.
10. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumabfor relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
11. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-316.
12. Von Mehren M, Britten C, Lear K, et al. Phase I, dose-escalation study of BIIB022 (anti-IGF-1 R antibody) in advanced solid tumors. J Clin Oncol 2010; 28 (Suppl):15s; abstract 2612.
13. Newman R, Hariharan K, Reff M, et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4\+ T cells in chimpanzees. Clin Immunol 2001; 98:164-174.
14. Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-771.
15. Tao MH, Smith RIF, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993; 178:661-667.
16. Brekke OH, Michaelsen TE, Aase A, et al. Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. Eur J Immunol 1994; 24:2542-2547.
17. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991; 173:1483-1491.
18. Petersen JG, Dorrington KJ. An in vitro system for studying the kinetics of interchain disulfide bond formation in immunoglobulin G. J Biol Chem 1974; 249:5633-5641.
19. Kabat EA, Wu TT, Perry HM, et al. Sequences of proteins of immunological interest. Bethesda: US Department of Health and Human Services, NIH; 1991.
20. Bloom JW, Madanat MS, Marriott D, etal. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 1997; 6:407-415.
21. Schuurman J, Perdok GJ, Gorter AD, et al. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1-8.
22. Taylor FR, Prentice HL, Garber EA, et al. Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody. Anal Biochem 2006; 353:204-208.
23. Angal S, King DJ, Bodmer MW, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105-108.
24. Aalberse RC, Stapel SO, Schuurman J, et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39:469-477.
25. Van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-1557.
26. Hussain R, Poindexter RW, Ottesen EA. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J Immunol 1992; 148:2731-2737.
27. Jeannin P, Lecoanet S, Delneste Y, etal. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160:3555-3561.
28. Horner AA, Widhopf GF, Burger JA, et al. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol 2001; 108:417-423.
29. Aalberse RC, Platts-Mills TA. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004; 113:983-986.
30. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114:1389-1397.
31. Wood N, Bourque K, Donaldson DD, et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol 2004; 231:133-145.
32. Tangye SG, Liu YJ, Aversa G, et al. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998; 188:1691-1703.
33. Stone JH, Caruso PA, Deshpande V. 2009. Case records of the Massachusetts General Hospital. Case 24-2009: a 26 year old woman with painful swelling of the neck. N Engl J Med 2009; 361: 511-518.
34. Dahlgren MN, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res. 2010; 62:1312-1318.
35. Stone JH, Khosroshahi A, Deshpande V, Stone JR. IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Rheum 2010; 62:316-322.
36. Rock B, Martins CR, Theofilopoulos AN, etal. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320:1463-1469.
37. Holland M, Hewins P, Goodall M, et al. Antineutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 2004; 138:183-192.
38. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, nonmito-genic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-411.
39. Armour KL, Van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003; 40:585-593.
40. Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68:1310-1315.
41. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62:1755-1762.